Mast cells and pancreatic cancer.

  title={Mast cells and pancreatic cancer.},
  author={Theoharis C. Theoharides},
  journal={The New England journal of medicine},
  volume={358 17},
  • T. Theoharides
  • Published 24 April 2008
  • Biology, Medicine
  • The New England journal of medicine
Pancreatic ductal adenocarcinoma is probably the most lethal cancer, with a median survival of less than 6 months and a 5-year survival rate of less than 5%. The cause of pancreatic ductal adenocarcinoma is unknown, and this type of cancer resists all currently available treatments. Increasing evidence indicates that inflammation around tumors, including infiltration by mast cells, facilitates cancer growth, especially that of pancreatic ductal adenocarcinoma.1 Mast cells are derived from a… 

Figures from this paper

Increased Number of Non-Degranulated Mast Cells in Pancreatic Ductal Adenocarcinoma but Not in Acute Pancreatitis

MC are increased in number, but not degranulated in PDAC, suggesting that they may contribute to cancer growth by permitting selective release of pro-tumorogenic molecules.

Role of the tumor microenvironment in pancreatic adenocarcinoma.

The cellular microenvironment of pancreatic ductal adenocarcinoma (PDA), the major type of Pancreatic cancer, is described and it is hoped that a better understanding of the cellular micro environment of PDA will eventually lead to better treatments for this disease.

Mast cells and angiogenesis in pancreatic ductal adenocarcinoma

This review will summarize the literature concerning the mast cells infiltration in the pancreatic ductal adenocarcinoma analyzing its role in angiogenesis and tumor progression.

Mast Cells and Tumor Microenvironment

Evidence indicates that a unique immune cell, the mast cell, accumulates in the stroma surrounding certain tumors, especially mammary and pancreatic adenocarcinoma, as well as melanoma, where blocking the release of pro-tumor mediators may constitute a novel therapeutic approach.

Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

It is found that mast cells are essential for PDAC tumorigenesis and exacerbate the cellular and extracellular dynamics of the tumor microenvironment found in PDAC, and targeting mast cells may inhibit stromal formation and improve therapy.

Molecular Analysis of Precursor Lesions in Familial Pancreatic Cancer

An identified 76-gene signature of PDAC progression presents a rich candidate pool for the development of early diagnostic and/or surveillance markers as well as potential novel preventive/therapeutic targets for both familial and sporadic pancreatic adenocarcinoma.

Mast cells and immune response in cancer

Results obtained in mouse models have demonstrated that mast cells influence tumor progression, thanks to their ability to promote angiogenesis, modulate antitumor immune responses, and regulate tumor growth.

A concept of Helicobacter pylori and stress-secreted mast cells' potential involvement in brain metastases

IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization

It is shown, using genetic mouse models, that in gastric cancer, mast cells at the periphery of the tumors are activated via cancer cell produced-IL33 and promote tumorigenesis by recruiting macrophages within the tumors.



Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma

Mononuclear inflammatory cells of the non-specific immune response are recruited to pancreatic cancer tissues independent of the presence of CP-like changes, may influence the metastatic capacity of the cancer cells, and may contribute to the development of tumours with high angiogenic activity.

Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors

It is shown in a β-cell tumor model that activation of Myc in vivo triggers rapid recruitment of mast cells to the tumor site—a recruitment that is absolutely required for macroscopic tumor expansion.

Differential release of mast cell mediators and the pathogenesis of inflammation

Understanding this process could help develop mast cell inhibitors of selective mediator release with novel therapeutic applications, as it appears to involve de novo synthesis of mediators, such as interleukin‐6 and vascular endothelial growth factor, with release through secretory vesicles similar to those in synaptic transmission.

Human Mast Cells Express Corticotropin-Releasing Hormone (CRH) Receptors and CRH Leads to Selective Secretion of Vascular Endothelial Growth Factor1

This work reports the first evidence that mast cells express functional CRH receptors and that CRH can induce VEGF secretion selectively, which could be involved in chronic inflammatory conditions associated with increased V EGF, such as arthritis or psoriasis.

Mast cells in the development of adaptive immune responses

Mast cells may influence the development, intensity and duration of adaptive immune responses that contribute to host defense, allergy and autoimmunity, rather than simply functioning as effector cells in these settings.